Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Gilead withdraws bladder cancer drug in US
Gilead withdraws bladder cancer drug in US after failed trial
Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients with a type of bladder cancer after consultation with the U.S. health regulator. The U.
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high NSCLC. Started in February 2023, the trial currently bears a primary completion date in January 2027.
Drugmaker Pulls Trodelvy's Bladder Cancer Approval
Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences announced on Friday. The decision was made in consultation with the FDA and does not affect the antibody-drug conjugate's other indications,
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year.
Gilead withdraws bladder cancer drug Trodelvy in US
Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients with a type of bladder cancer after consultation with the U.S.
FDA Accepts New Drug Application for UGN-102 in Bladder Cancer
The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk non–muscle-invasive bladder cancer.
Gilead withdraws Trodelvy in bladder cancer
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval in that indication.
Parade on MSN
5d
This Is One of the Most Common Signs of Bladder Cancer, According to a Urogynecologist
Dr. Kobashi says that the most common symptom of bladder cancer is blood in urine. The blood can range from bright red to a ...
Asia One
1d
'I try not to think about myself': Woman battles breast cancer while caring for mum who has gall bladder cancer
To mark Breast Cancer Awareness Month, we speak to inspiring Singaporeans about their journey in battling and overcoming ...
2d
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease
Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising ...
6d
Breakthrough Study Reveals How Bladder Cancer Starts and Spreads
Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...
FierceBiotech
3d
Aura's virus-based drug regimen eradicates tumors in 4 out of 5 low-grade bladder cancer patients
With its lead candidate in a phase 3 trial for a rare eye
cancer
, Aura Biosciences is looking to expand the drug into a ...
Mid Day
15h
Cancer patients nearly 5 times more likely to go bankrupt, find researchers
Cancer patients are nearly five times more likely to experience bankruptcy, as financial fallout can follow patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Gilead
United States
Trodelvy
Food and Drug Administration
Feedback